EA201791970A1 - Способ лечения первичного склерозирующего холангита - Google Patents

Способ лечения первичного склерозирующего холангита

Info

Publication number
EA201791970A1
EA201791970A1 EA201791970A EA201791970A EA201791970A1 EA 201791970 A1 EA201791970 A1 EA 201791970A1 EA 201791970 A EA201791970 A EA 201791970A EA 201791970 A EA201791970 A EA 201791970A EA 201791970 A1 EA201791970 A1 EA 201791970A1
Authority
EA
Eurasian Patent Office
Prior art keywords
holangitis
sclerosed
treating primary
subject
treating
Prior art date
Application number
EA201791970A
Other languages
English (en)
Russian (ru)
Inventor
Брихад Абхианкар
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201791970A1 publication Critical patent/EA201791970A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
EA201791970A 2015-03-06 2016-03-04 Способ лечения первичного склерозирующего холангита EA201791970A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562129698P 2015-03-06 2015-03-06
PCT/US2016/020819 WO2016144720A1 (en) 2015-03-06 2016-03-04 Method of treating primary sclerosing cholangitis

Publications (1)

Publication Number Publication Date
EA201791970A1 true EA201791970A1 (ru) 2018-07-31

Family

ID=55699788

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791970A EA201791970A1 (ru) 2015-03-06 2016-03-04 Способ лечения первичного склерозирующего холангита

Country Status (11)

Country Link
US (2) US20180051086A1 (https=)
EP (2) EP4257200A3 (https=)
JP (1) JP6942053B2 (https=)
KR (1) KR20170120622A (https=)
AU (1) AU2016229193A1 (https=)
BR (1) BR112017019071A2 (https=)
CA (1) CA2978725A1 (https=)
EA (1) EA201791970A1 (https=)
MA (1) MA41636A (https=)
MX (1) MX2017011272A (https=)
WO (1) WO2016144720A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
IL261750B2 (en) * 2016-03-14 2024-07-01 Millennium Pharm Inc Method of preventing graft versus host disease
BR112018068625A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro
CN109414502A (zh) 2016-06-12 2019-03-01 千禧制药公司 治疗炎症性肠病的方法
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
US20220267449A1 (en) * 2019-06-10 2022-08-25 Takeda Pharmaceutical Company Limited METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY
WO2022075756A1 (ko) 2020-10-08 2022-04-14 주식회사 큐롬바이오사이언스 베타-라파촌을 유효성분으로 포함하는 담즙 정체성 간질환 예방 또는 치료용 약학 조성물
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
DE69940503D1 (de) * 1998-05-13 2009-04-16 Genentech Inc Diagnose und behandlung von hepatischen krankheiten
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive

Also Published As

Publication number Publication date
EP3265492A1 (en) 2018-01-10
JP2018508526A (ja) 2018-03-29
MX2017011272A (es) 2018-01-12
US20180051086A1 (en) 2018-02-22
US12391760B2 (en) 2025-08-19
KR20170120622A (ko) 2017-10-31
EP4257200A3 (en) 2024-01-03
US20210388092A1 (en) 2021-12-16
EP4257200A2 (en) 2023-10-11
WO2016144720A1 (en) 2016-09-15
JP6942053B2 (ja) 2021-09-29
AU2016229193A1 (en) 2017-09-21
BR112017019071A2 (pt) 2018-04-17
MA41636A (fr) 2018-01-09
CA2978725A1 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
EA201791970A1 (ru) Способ лечения первичного склерозирующего холангита
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
MX382549B (es) Combinación con anticuerpos anti-cd40 y anticuerpos anti-pd-1.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201892480A1 (ru) Соединения, модулирующие fxr (nr1h4)
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201892482A1 (ru) Соединения, модулирующие fxr (nr1h4)
MX388181B (es) Anticuerpos anti-pd-1.
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201891925A1 (ru) Антитела к cd40 с усиленной агонистической активностью
MX391141B (es) Anticuerpos anti-ceramida.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2017004196A (es) Anticuerpos contra ticagrelor y metodos de uso.
EA201992522A1 (ru) КОМБИНАЦИЯ БИСПЕЦИФИЧЕСКОГО АНТИТЕЛА К ErbB-2/ErbB-3 С ЭНДОКРИННОЙ ТЕРАПИЕЙ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
BR112017025264A2 (pt) tratamento de prurido
MX386543B (es) Anticuerpo de anti-esclerostina, fragmento de unión a antigeno y uso médico del mismo.
MX378452B (es) Anticuerpos monoclonales anti-+)--metanfetamina.